Timing of quality of life assessment in cancer clinical trials: fine tuning remains a challenge by Bernhard, J.
Editorial
Timing of quality of life assessment in cancer
clinical trials: fine tuning remains a challenge
Over the past decades, hundreds of different quality of life-
related measures have been published, including generic
(general) and disease or treatment-specific measures to be
used in cancer patients. ‘Just give me the best quality of life
questionnaire’ is a familiar request to those involved in quality
of life research, especially those collaborating with clinicians
who conduct clinical trials. This simple question exposes a
morass of complexity. Usually there is at least some empirical
evidence to assist the choice, but that depends critically upon
the research question and the corresponding study design.
In a recent phase-III trial by Saad et al. in hormone–refractory
prostate cancer, patients receiving the bisphosphonate zoledro-
nic acid experienced fewer skeletal-related events and a longer
time until the first skeletal-related event as compared to those
receiving placebo [1]. The skeletal-related events, comprising
pathologic bone fractures, spinal cord compression, surgery
and radiation therapy to bone or a change of antineoplastic
therapy to treat bone pain, might reasonably be expected to
impact on patients’ quality of life. Yet the investigators found
no corresponding treatment differences in health-related qua-
lity of life as measured by three different types of validated
questionnaires, a cancer-specific quality of life questionnaire
(FACT-G) [2], a pain questionnaire (BPI) [3] and a health
state profile (EuroQol) [4] at three months intervals.
These negative quality of life findings led to a questioning
of the clinical relevance of skeletal-related events [5, 6]. Are
quality of life measures really a valid and responsive measure
relevant to this research question [7]?
Such results bolster the prejudices of those who think that
measuring quality of life endpoints in cancer clinical trials is a
mere tribute to political correctness. More than half a century
ago, Karnofsky and Burchenal in their landmark paper enun-
ciated the case for objective measurement: “. . . In the absence
of coincident and significant objective evidence of a thera-
peutic effect, subjective improvement is a notoriously poor
method of evaluating a therapeutic agent against cancer . . . ”
[8]. As an alternative to a ‘subjective’ measure they intro-
duced standardized measures of functional status which have
influenced assessment of cancer patients ever since. In the
study by Saad et al., despite the suggestion of benefit there
was no statistically significant difference in ECOG perform-
ance status among the treatment groups.
In this issue of Annals of Oncology, Weinfurt and
colleagues [9] present a secondary analysis of the data
by Saad et al. They investigated the clinical relevance of
skeletal-related events in terms of their impact on patients’
trajectories of quality of life, pain and health state preferences
by assessing changes after each patient’s first skeletal-related
event. Skeletal-related events appeared to have clinically
meaningful effects on the different quality of life measures.
The authors conclude that using fixed 3-month assessments,
especially when the interval between visits is longer than it
takes for the acute event to resolve, may not provide good esti-
mates of the patient’s underlying trajectory. In this situation, it
is unlikely that a sensitive treatment comparison can be made.
What should these considerations teach us for future trials?
As Weinfurt and colleagues conclude, investigators designing
trials involving repeated acute events should consider event-
triggered data collection or more intensive, diary-type assess-
ments. Event-triggered data collection is a new interesting
strategy for cancer clinical trials. It may require close patient
monitoring to capture the relevant events. Diaries have fre-
quently been used in different clinical trial settings. Their
responsiveness to symptoms and side-effects is well estab-
lished. However, missing data is an issue [10]. Recent devel-
opments of electronic diaries such as self-report by palm-top
or mobile phone short message service may overcome some
of these difficulties and may also be used for event-triggered
data collection. Such strategies raise new methodological
questions [11], especially in defining a clinically meaningful
difference from a longitudinal perspective.
From a clinical point of view we are interested in the patient’s
overall experience of quality of life over the time of the relevant
intervention, rather than in widely spaced single point estimates.
Defining the appropriate assessment interval for this purpose is
not trivial. In the trial by Saad et al., a monthly schedule might
have resulted in a different conclusion regarding quality of life.
The assessment interval depends not only on the question to be
addressed and the clinical factors but also on practical and con-
ceptual issues. A comprehensive quality of life assessment, con-
sidered as ‘best practice’ by many, might however involve
multiple generic and disease- or treatment-specific measures
(e.g., 30 to 50 questions) which may not be feasible in a confined
clinical context. Especially in the palliative setting patient
burden should be kept to a minimum both for humanitarian
reasons and because it is a source of missing data.
Can we ‘keep it simple’ for frequently repeated assessments?
Global indicators, such as for ‘quality of life’ itself [12, 13] or
for being bothered by treatment-related difficulties [14], are
responsive to the wide spectrum of reactions seen in patients on
and off treatment and may detect changes on single dimen-
sions, allowing for comparison across treatments. Indicators of
the most important symptoms and side-effects may comp-
lement the picture to an extent feasible even for diaries. We do
not have to reinvent the development of quality of life
measures: we can rely on existing short forms.
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Regular implementation of such strategies may allow for
new insight into the pattern of morbidity and adaptation. For
example, studies may explore why patients’ quality of life
scores may differ in variability across time rather than merely
reporting mean levels. Similarly, it is possible to examine
whether there are predictive factors for the subjective toler-
ance of toxic therapies (e.g., high dose chemotherapy). The
ultimate goal of measuring quality of life endpoints is to
empower patients’ voices in treatment evaluation. This can
only be reached when these measures are timed correctly: fine
tuning remains a challenge.
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